Delivery Order SPE2DR25D2104-SPE2DR26F3PQL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $73,540.08 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) with a completion deadline of April 30, 2025. This competitively awarded, firm fixed-price contract was issued on April 29, 2025, with no set-aside designation. The order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency (DLA) awarded a $49,532.30 delivery order to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) on November 13, 2025, with an ultimate completion date of November 14, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $43,249.85, represents a non-competitive award under the company's existing indefinite delivery contract with DLA. The order is scheduled for completion by November 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,074.77 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units). This non-competitive delivery order, issued on April 22, 2025, with completion by April 23, 2025, represents a firm fixed-price transaction under DLA's pharmaceutical procurement framework. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) valued at $8,107.66 under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical supplies to federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $8,025.05 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a small-value transaction under a larger federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,940.08 to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) with completion targeted for October 20, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a specific pharmaceutical product delivery under AmerisourceBergen's existing contract vehicle with...
- The Defense Logistics Agency awarded a delivery order valued at $11,428.25 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count unit of use packaging) on August 29, 2025, with completion scheduled for September 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical supply transaction for federal medical procurement. The work will be performed at AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $8,320.29 to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) on August 21, 2025, with completion scheduled for August 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $10,862.72 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) with a firm fixed-price structure. This non-set-aside competitive award was issued on May 30, 2025, with an ultimate completion date of June 2, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3PQLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,785.42 to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) on November 20, 2025, with completion scheduled for November 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other government agencies, including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio encompasses specialty medications, brand-name and generic drugs, vaccines, and specialized medical commodities across multiple therapeutic areas, positioning it as a primary pharmaceutical support provider for the Department of Defense's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 11/20/25 |